A large body of evidence supports the cardioprotective effects of the long-chain omega-3
polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA), and docosahexaenoic …

Background Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the primary
omega-3 fatty acids in fish oil, have been shown to reduce cardiovascular disease (CVD) …

The long-chain omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), are found in seafood, supplements, and concentrated pharmaceutical …

Omega-3 fatty acid supplements containing both eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) have been shown to reduce triglycerides but also increase …

Objective To conduct meta-analyses of randomized controlled trials (RCTs) to estimate the
effect of eicosapentaenoic and docosahexaenoic acid (EPA+ DHA) on coronary heart …

Background Over 200 clinical trials have examined the effect of eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) supplements on risk factors associated with …

The effects of eicosapentaenoic acid (EPA) 600 and 1800 mg/day and docosahexaenoic
acid (DHA) 600 mg/day versus olive oil placebo on cardiovascular disease (CVD) risk …

Background Recent studies suggest that eicosapentaenoic (EPA) and docosahexaenoic
(DHA) acids have distinct effects on cardiometabolic risk factors. The Omega-3 Index (O3I) …

In cardiology, results of recent large intervention trials with eicosapentaenoic acid (EPA)
plus docosahexaenoic acid (DHA) supplements were neutral. In contrast, in epidemiologic …

Compelling evidence exists for the cardioprotective benefits resulting from consumption of
fatty acids from fish oils, EPA (20: 5n-3) and DHA (22: 6n-3). EPA and DHA alter membrane …